BridgeBio Pharma, Inc.’s acoramidis found redemption, with the Phase III ATTRibute-CM showing positive results in transthyretin amyloid cardiomyopathy (ATTR-CM) as compared with the negative results at an interim analysis at the end of 2021. The positive Phase III data should carry the drug through to regulatory approval, but it may face commercial headwinds due to the entrenched position of Pfizer Inc.’s Vyndaqel/Vyndamax (tafamidis) franchise.
BridgeBio Comes Back With Positive Phase III Results For Acoramidis In ATTR-CM
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.